On August 3, 2026, a Phase 3 clinical trial update was recorded for cagrilintide. The trial, titled "Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide," is registered under identifier NCT07220759. Its current status is listed as active, not recruiting, meaning enrollment has closed but the study is still ongoing. This is a Phase 3 study, a late stage of clinical research typically used to evaluate a compound in larger patient populations. No results have been posted for this trial as of the update date. Cagrilintide remains classified as an unapproved compound under research and is not approved for medical use. The trial specifically involves people living with overweight or obesity who also have type 2 diabetes. No efficacy, safety, or outcome data are included in this update. Readers can find further details, including trial design and eligibility criteria, at the official clinicaltrials.gov listing. For more background on cagrilintide and its research status, see the compound overview.
Cagrilintide Phase 3 Trial in Overweight/Obesity and Type 2 Diabetes Now Active
See the full cagrilintide overview
Source: https://clinicaltrials.gov/study/NCT07220759